APP and early-onset autosomal dominant Alzheimer disease: Therefore, for our in silico studies, we resolved to utilize biomedically relevant affibodies, namely, a ZHER2-binding affibody (PDB ID: 2KZI), a candidate biotherapeutic alternative to monoclonal HER2-targeting antibody trastuzumab, an amyloid beta A4 protein-binding affibody (2OTK), which targets oligomers and aggregates of the amyloid-beta (Abeta) peptide found in Alzheimer’s disease, and a Protein A-binding affibody (1H0T), as model structures.